A dose-escalation study of pegylated liposomal doxorubicin and oxaliplatin in patients with advanced solid tumors

Oncology

Volumn 71, Issue 3-4, 2007, Pages 190-196

  Kotsakis, A ^a   Kouroussis, Ch ^a   Androulakis, N ^a   Agelaki, S ^a   Kalbakis, K ^a   Vamvakas, L ^a   Vardakis, N ^a   Kalykaki, A ^a   Polyzos, A ^b   Georgoulias, V ^a   Mavroudis, D ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Liposomal doxorubicin; Oxaliplatin; Phase I study; Tumors, solid

Indexed keywords

DEXAMETHASONE; DIAZEPAM; DOXORUBICIN; HEMOPOIETIC GROWTH FACTOR; ONDANSETRON; OXALIPLATIN;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BREAST CARCINOMA; CAUSE OF DEATH; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE ESCALATION; DRUG ERUPTION; EDEMA; ENDOMETRIUM CARCINOMA; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INFECTION; LUNG NON SMALL CELL CANCER; MACULOPAPULAR RASH; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVARY CARCINOMA; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; PRURITUS; SENSORY NEUROPATHY; SEPSIS; SIDE EFFECT; SOLID TUMOR; STOMACH CARCINOMA; THERAPY DELAY; THROMBOCYTOPENIA; THYROID CARCINOMA; TINNITUS; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; UTERINE CERVIX CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DOXORUBICIN; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; POLYETHYLENE GLYCOLS;

EID: 34548069117     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000106068     Document Type: Article

References (34)

1. Working PK, Newman MS, Huang SK: Pharmacokinetics, biodistribution and therapeutic efficacy of doxorubicin encapsulated in stealth liposomes (Doxil). J Liposome Res 1994;4:667-687.
2. Batist G, Harris L, Azarnia N, Lee LW, Daza-Ramirez P: Improved antitumor response rate with decreased cardiotoxicity of nonpegylated liposomal doxorubicin compared with conventional doxorubicin in first line treatment of metastatic breast cancer patients who had received prior adjuvant doxorubicin: results of retrospective analysis. Anticancer Drugs 2006;17:587-595.
3. O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C: Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440-449.
4. Al-Batran SE, Bischoff J, von Minckwitz G, Atmaca A, Kleeberg U, Meuthen I, Morack G, Lerbs W, Hecker D, Sehouli J, Knuth A, Jager E: The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicenter phase II trial. Br J Cancer 2006;94:1615-1620.
5. Gabizon AA, Lyass O, Berry GJ, Wildgust M: Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies. Cancer Invest 2004;22:663-669.
6. Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z, Libson E, Muggia FM, Gabizon A: Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995;13:1777-1785.
7. Chia S, Clemons M, Martin LA, Rodgers A, Gelmon K, Pond GR, Panasci L: Pegylated liposomal doxorubicin and trastuzumab in Her-2 overexpressing metastatic breast cancer: a multicentre phase II trial. J Clin Oncol 2006;24:2773-2778.
8. Al-Batran SE, Meerpohl HG, von Minckwitz G, Atmaca A, Kleeberg U, Harbeck N, Lerbs W, Hecker D, Sehouli J, Knuth A, Jager E: Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m 2 every 4 weeks in previously treated patients with metastatic breast cancer. Oncology 2006;70:141-146.
9. Valerio MR, Tagliaferri P, Raspagliesi F, Fulfaro F, Badalamenti G, Arcara C, Cicero G, Russo A, Venuta S, Guarneri G, Gebbia N: A phase II study of pegylated liposomal doxorubicin, oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinomas. Int J Gynecol Cancer 2006;16:79-85.
10. Sessa S, Marsoni S: Randomized singleagents trials in recurrent epithelial ovarian cancer. Int J Gynecol Cancer 2005;15:247-251.
11. Muggia F, Hamilton A: Phase III data on Caelyx in ovarian cancer. Eur J Cancer 2001;37:S15-S18.
12. Le LH, Swenerton KD, Elit L, Provencher DM, Stuart GC, Le T, Lee U, Rodgers A, Pond GR, Hu H, Oza AM: Phase II multicenter open-label study of carboplatin and pegylated liposomal doxorubicin in uterine and cervical malignancies. Int J Gynecol Cancer 2005;15:799-806.
13. Faivre S, Alsabe H, Djafari L, Janot F, Julieron M, Domenge C, Djazouli K, Armand JP, Luboinski B, Raymond E: Locoregional effects of pegylated liposomal doxorubicin in irradiated area: a phase I-II study in patients with recurrent squamous cell carcinoma of the head and neck. Eur J Cancer 2004;40:1517-1521.
14. Janinis J, Stathopoulos GP, Nikolaidis P, Kalofonos HP, Kalogera-Fountzila A, Samantas E, Aravantinos G, Anagnostopoulos A, Tolis C, Makatsoris T, Rigatos SK, Bafaloukos D, Dimopoulos MA, Daniilidis J, Fountzilas G: Pegylated liposomal doxorubicin hydrochloride and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). Anticancer Drugs 2004;15:479-487.
15. Dummer R: Future perspectives in the treatment of cutaneous T-cell lymphoma. Semin Oncol 2006;33:S33-S36.
16. Hussein MA, Anderson KC: Role of liposomal antracyclines in the treatment of multiple myeloma. Semin Oncol 2004;31:147-169.
17. Raymond E, Faivre S, Woynarowski JM, Chaney SG: Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998;25:4-12.
18. Scartozzi M, Franciosi V, Campanini N, Benedetti G, Barbieri F, Rossi G, Berardi R, Camisa R, Silva RR, Santinelli A, Ardizzoni A, Crino L, Rindi G, Cascinu S: Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer patients. Lung Cancer 2006;53:103-109.
19. Dieras V, Girre V, Guilhaume MN, Laurence V, Mignot L: Oxaliplatin and ovarian cancer. Bull Cancer 2006;93:S35-S39.
20. Petit T, Benider A, Yovine A, Bougnoux P, Spaeth D, Maindrault-Goebel F, Serin D, Tigaud JD, Eymard JC, Simon H, Bertaux B, Brienza S, Cvitkovic E: Phase II study of an oxaliplatin/vinorelbine combination in patients with antracycline- and taxane-pretreated metastatic breast cancer. Anticancer Drugs 2006;17:337-343.
21. Culine S: Oxaliplatin in genitourinary tumors. Bull Cancer 2006;93:S41-S43.
22. Soulie P, Garrino C, Bensmaine MA, Bekradda M, Brain E, Di Palma M, Goupil A, Misset JL, Cvitkovic E: Antitumoral activity of oxaliplatin/ cisplatin-based combination therapy in cisplatin refractory germ cell cancer patients. Cancer Res Clin Oncol 1999;125:707-712.
23. Sumpter K, Harper-Wynne C, Cunningham D, Rao S, Tebbutt N, Norman AR, Ward C, Iveson T, Nicolson M, Hickish T, Hill M, Oates J: Report of two protocol planned interim analyses in a randomized multicentre phase III study comparing capecitabine with floracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer 2005;92:1976-1983.
24. Extra JM, Marty M, Brienza S, Misset JL: Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 1998;25:13-22.
25. Robbins GK: Fever in the neutropenic adult patient with cancer. UpToDate 2005;13.3.
26. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS: 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730.
27. Rolston KV: Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia. Clin Infect Dis 2005;40:246-252.
28. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981;47:207-214.
29. Recchia F, De Filippis S, Saggio G, Amiconi G, Cesta A, Carta G, Rea S: Phase I study of liposomal doxorubicin and oxaliplatin as salvage chemotherapy in advanced ovarian cancer. Anticancer Drugs 2003;14:633-638.
30. Nicoletto MO, Falci C, Pianalto D, Artioli G, Azzoni P, De Masi G, Ferrazzi E, Perin A, Donach M, Zoli W: Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer. Gynecol Oncol 2006;100:318-323.
31. Amantea M, Newman MS, Sullivan TM, Forrest A, Working PK: Relationship of dose intensity to the induction of palmar-plantar erythrodysesthesia by pegylated liposomal doxorubicin in dogs. Hum Exp Toxicol 1999;18:17-26.
32. Hubert A, Lyass O, Pode D, Gabizon A: Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer. Anticancer Drugs 2000;11:123-127.
33. 2) in the treatment of gynaecologic cancers. Gynecol Oncol 2005;97:374-378.
34. Rose PG: Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. Oncologist 2005;10:205-214.